WallStreetZenWallStreetZen

NASDAQ: LGND
Ligand Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for LGND

Based on 2 analysts offering 12 month price targets for Ligand Pharmaceuticals Inc.
Min Forecast
$95.00+29.96%
Avg Forecast
$119.50+63.47%
Max Forecast
$144.00+96.99%

Should I buy or sell LGND stock?

Based on 2 analysts offering ratings for Ligand Pharmaceuticals Inc.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their LGND stock forecasts and price targets.

LGND stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-02-29
lockedlocked$00.00+00.00%2023-12-13

1 of 1

Forecast return on equity

Is LGND forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is LGND forecast to generate an efficient return on assets?
Insufficient data to display

LGND revenue forecast

What is LGND's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$139.3M
Avg 2 year Forecast
$155.8M
Avg 3 year Forecast
$184.0M

LGND vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LGND$73.10$119.50+63.47%Strong Buy
VRNA$16.09$32.50+101.99%Buy
ABCL$4.53$14.33+216.40%Strong Buy
PRTA$24.77$68.14+175.10%Buy
TARS$36.35$48.00+32.05%Buy

Ligand Pharmaceuticals Stock Forecast FAQ

Is Ligand Pharmaceuticals Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: LGND) stock is to Strong Buy LGND stock.

Out of 2 analysts, 1 (50%) are recommending LGND as a Strong Buy, 1 (50%) are recommending LGND as a Buy, 0 (0%) are recommending LGND as a Hold, 0 (0%) are recommending LGND as a Sell, and 0 (0%) are recommending LGND as a Strong Sell.

If you're new to stock investing, here's how to buy Ligand Pharmaceuticals stock.

What is LGND's revenue growth forecast for 2024-2026?

(NASDAQ: LGND) Ligand Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 62.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.6%.

Ligand Pharmaceuticals's revenue in 2024 is N/A.On average, 2 Wall Street analysts forecast LGND's revenue for 2024 to be $2,465,461,215, with the lowest LGND revenue forecast at $2,429,165,376, and the highest LGND revenue forecast at $2,501,757,053. On average, 2 Wall Street analysts forecast LGND's revenue for 2025 to be $2,757,686,977, with the lowest LGND revenue forecast at $2,723,073,141, and the highest LGND revenue forecast at $2,792,300,813.

In 2026, LGND is forecast to generate $3,257,595,755 in revenue, with the lowest revenue forecast at $3,257,595,755 and the highest revenue forecast at $3,257,595,755.

What is LGND's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: LGND) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 5.37%.

What is LGND's Price Target?

According to 2 Wall Street analysts that have issued a 1 year LGND price target, the average LGND price target is $119.50, with the highest LGND stock price forecast at $144.00 and the lowest LGND stock price forecast at $95.00.

On average, Wall Street analysts predict that Ligand Pharmaceuticals's share price could reach $119.50 by Feb 28, 2025. The average Ligand Pharmaceuticals stock price prediction forecasts a potential upside of 63.47% from the current LGND share price of $73.10.

What is LGND's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: LGND) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.